What medication is recommended for a pediatric patient with functional urinary incontinence (e.g., primary nocturnal enuresis or overactive bladder)?

Medication for Pediatric Urinary Incontinence

For pediatric patients with nocturnal enuresis (bedwetting), desmopressin is the first-line pharmacological treatment, dosed at 0.2-0.4 mg orally taken 1 hour before sleep, with immediate effect expected. 1

Treatment Algorithm by Clinical Presentation

For Monosymptomatic Nocturnal Enuresis (bedwetting only, no daytime symptoms)

First-line pharmacotherapy:

• Desmopressin (oral tablets preferred over nasal spray due to hyponatremia risk)
  • Dose: 0.2-0.4 mg taken 1 hour before bedtime
  • Effect is immediate if it will work
  • 30% achieve complete dryness, 40% partial response 1, 2
  • Most effective in children with nocturnal polyuria (nighttime urine production >130% of expected bladder capacity) 1
  • Critical safety warning: Restrict evening fluid intake to ≤200 mL (6 oz) to prevent water intoxication and hyponatremia with seizures 1

Second-line (if desmopressin fails):

• Anticholinergics - only after standard treatment failure 1
  • Oxybutynin 5 mg at bedtime (may double)
  • Tolterodine 2 mg at bedtime (may double)
  • Propiverine 0.4 mg/kg at bedtime (may double)
  • Often combined with desmopressin for better effect
  • Effective in ~40% of treatment-resistant cases 1
  • Must exclude: constipation, post-void residual urine, low voiding frequency before prescribing
  • Side effects: constipation (most common), urinary retention risk, mood changes 1

Third-line:

• Imipramine 25-50 mg at bedtime (only at tertiary centers due to cardiotoxicity risk) 1
  • 50% response rate but significant safety concerns
  • Potentially fatal in overdose
  • Requires cardiac screening if family history of arrhythmia or sudden death 1

For Overactive Bladder with Daytime Symptoms

First-line pharmacotherapy:

• Anticholinergics (after behavioral therapy)
  • Oxybutynin (FDA-approved for pediatrics) 3
  • Propiverine (FDA-approved for pediatrics) 3
  • Solifenacin showed superiority over placebo in children 5-12 years, increasing mean voided volume by 12.1 mL 4
  • Tolterodine (commonly used off-label)

For reduced bladder capacity without daytime symptoms:

• This affects 27.8% of primary enuresis cases 5
• Anticholinergics or beta-3 agonists increase bladder capacity effectively
• After 3 months: maximal voided volume increased from 117.5 mL to 183.3 mL 5
• 41.7% complete improvement, 25% partial improvement 5

Combination Therapy Strategies

Desmopressin + Anticholinergics:

• May increase children achieving 14 consecutive dry nights (RR 1.53) 2
• Consider when monotherapy fails
• Monitor for additive side effects 2

Desmopressin + Alarm therapy:

• Probably reduces wet nights compared to alarm alone (MD -0.88) 2
• May increase success rate compared to desmopressin alone (RR 1.26) 2

Critical Pre-Treatment Requirements

Before prescribing any medication:

1. Exclude/treat constipation first - bladder and bowel dysfunction are interrelated 1
2. Complete frequency-volume chart to assess bladder capacity and voiding patterns 1
3. Measure post-void residual if considering anticholinergics 1
4. Screen for polydipsia - absolute contraindication to desmopressin 1
5. Urinalysis to exclude infection or diabetes 1

Common Pitfalls to Avoid

• Never use desmopressin nasal spray - higher hyponatremia risk, indication removed in many countries 1
• Don't prescribe anticholinergics without checking post-void residual - risk of urinary retention and UTIs 1
• Don't use imipramine as first-line - cardiotoxicity makes it third-line only 1
• Don't treat nocturnal enuresis in children with daytime symptoms until daytime bladder dysfunction is addressed first 6
• Don't forget regular drug holidays with desmopressin to assess ongoing need 1

Monitoring Parameters

• Desmopressin: Immediate effect expected; if no response after proper trial, reassess diagnosis 1
• Anticholinergics: Effect should appear within 2 months maximum 1
• Watch for decreasing efficacy with anticholinergics - may signal developing constipation 1
• Monthly follow-up to sustain motivation and adjust therapy 1

The evidence strongly supports desmopressin as first-line pharmacotherapy for monosymptomatic nocturnal enuresis, with anticholinergics reserved for treatment-resistant cases or when daytime overactive bladder symptoms coexist. The 2010 International Children's Continence Society guidelines [1-1 provide the framework, with recent research 2, 5 confirming these recommendations remain valid.